By a News Reporter-Staff News Editor at Hematology Week -- Research findings on Nitric Oxide are discussed in a new report. According to news originating from Houston, Texas, by NewsRx correspondents, research stated, "This study aimed to demonstrate whether pretreatment with nitric oxide (NO) loaded into echogenic immunoliposomes (ELIP) plus ultrasound, applied before injection of molecularly targeted ELIP can promote penetration of the targeted contrast agent and improve visualization of atheroma components. ELIP were prepared using the pressurization-freeze method."
Our news journalists obtained a quote from the research from Texas Heart Institute, "Atherosclerosis was induced in Yucatan miniswine by balloon denudation and a hyperlipidemic diet. The animals were randomized to receive anti-intercellular adhesion molecule-1 (ICAM-1) ELIP or immunoglobulin (IgG)-ELIP, and were subdivided to receive pretreatment with standard ELIP plus ultrasound, NO-loaded ELIP, or NO-loaded ELIP plus ultrasound. Intravascular ultrasound (IVUS) data were collected before and after treatment. Pretreatment with standard ELIP plus ultrasound or NO-loaded ELIP without ultrasound resulted in 9.2 +/- 0.7% and 9.2 +/- 0.8% increase in mean gray scale values, respectively, compared to baseline (p < 0.001 vs. control). Pretreatment with NO-loaded ELIP plus ultrasound activation resulted in a further increase in highlighting with a change in mean gray scale value to 14.7 +/- 1.0% compared to baseline (p < 0.001 vs. control). These differences were best appreciated when acoustic backscatter data values (RF signal) were used [22.7 +/- 2.0% and 22.4 +/- 2.2% increase in RF signals for pretreatment with standard ELIP plus ultrasound and NO-loaded ELIP without ultrasound respectively (p < 0.001 vs. control), and 40.0 +/- 2.9% increase in RF signal for pretreatment with NO-loaded ELIP plus ultrasound (p < 0.001 vs. control)]. NO-loaded ELIP plus ultrasound activation can facilitate anti-ICAM-1 conjugated ELIP delivery to inflammatory components in the arterial wall."
According to the news editors, the research concluded: "This NO pretreatment strategy has potential to improve targeted molecular imaging of atheroma for eventual true tailored and personalized management of cardiovascular diseases."
For more information on this research see: Nitric oxide improves molecular imaging of inflammatory atheroma using targeted echogenic immunoliposomes. Atherosclerosis, 2013;231(2):252-260. Atherosclerosis can be contacted at: Elsevier Ireland Ltd, Elsevier House, Brookvale Plaza, East Park Shannon, Co, Clare, 00000, Ireland. (Elsevier - www.elsevier.com; Atherosclerosis - www.elsevier.com/wps/product/cws_home/522790)
The news correspondents report that additional information may be obtained from H. Kim, Texas Heart Inst, Dept. of Pathol, Houston, TX 77025, United States. Additional authors for this research include P.H. Kee, Y. Rim, M.R. Moody, M.E. Klegerman, D. Vela, S.L. Huang, D.D. McPherson and S.T. Laing (see also Nitric Oxide).
Keywords for this news article include: Texas, Houston, Chemicals, Chemistry, Nitric Oxide, United States, Nanotechnology, Nitrogen Oxides, Molecular Imaging, Emerging Technologies, North and Central America, Reactive Nitrogen Species
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC